Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | CCR6 | P51684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28132939 | 1.00 | GSK3A (0.58) | GSK3AGSK3BCCR6 | |
| Acetic Acid SCHEMBL28472906 | 0.89 | GSK3A (0.46) | GSK3AGSK3BCCR6 | |
| Acetic Acid SCHEMBL28899322 | 0.89 | GSK3A (0.46) | GSK3AGSK3BCCR6 | |
| Acetic Acid SCHEMBL28462827 | 0.89 | GSK3A (0.46) | GSK3AGSK3BCCR6 | |
| SCHEMBL28099296 | 0.86 | GSK3A (0.48) | GSK3AGSK3BCCR6 | |
| Ethylene Glycol SCHEMBL169532 | 0.80 | GSK3A (0.69) | GSK3AGSK3BCCR6 | |
| Tromethamine SCHEMBL10712356 | 0.80 | GSK3A (0.52) | GSK3AGSK3BCCR6 | |
| Alcohol SCHEMBL4116686 | 0.78 | GSK3A (0.65) | GSK3AGSK3BCCR6 | |
| SCHEMBL10990 | 0.76 | — | — | |
| SCHEMBL33524954 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292657-A1 | Reduced side-effect hemoglobin compositions | Baxter Biotech Technology S.A.R.L. (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-7211560-B2 | Reduced side-effect hemoglobin compositions | BAXTER INTERNATIONAL, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20040259769-A1 | Reduced side-effect hemoglobin compositions | BAXTER INTERNATIONAL INC. | 2004-12-23 | — | — | US | disclosed |
| US-6670323-B1 | Hemoglobulin mutations for oxygen delivery | BAXTER INTERNATIONAL, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1233986-A4 | REDUCED SIDE-EFFECT HEMOGLOBIN COMPOSITIONS | BAXTER BIOTECH TECH SARL (CH) | 2003-01-02 | — | — | EP | disclosed |
| EP-1233986-A1 | REDUCED SIDE-EFFECT HEMOGLOBIN COMPOSITIONS | Baxter Biotech Technology S.A.R.L. (CH) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001034648-A1 | REDUCED SIDE-EFFECT HEMOGLOBIN COMPOSITIONS | BAXTER INTERNATIONAL, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259769-A1 | Reduced side-effect hemoglobin compositions | HBG1, HBB, HBG2 | GSK3A 1197/4885GSK3B 1227/4885CCR6 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.